Geoff Meacham
Stock Analyst at Citigroup
(3.74)
# 660
Out of 4,781 analysts
237
Total ratings
55.1%
Success rate
4.63%
Average return
Main Sectors:
Stocks Rated by Geoff Meacham
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
MRNA Moderna | Initiates: Neutral | $40 | $31.48 | +27.06% | 10 | Mar 13, 2025 | |
KYMR Kymera Therapeutics | Initiates: Buy | $52 | $30.39 | +71.11% | 4 | Mar 13, 2025 | |
KNSA Kiniksa Pharmaceuticals International, | Initiates: Buy | $40 | $22.76 | +75.75% | 3 | Mar 13, 2025 | |
BNTX BioNTech SE | Initiates: Buy | $145 | $95.90 | +51.20% | 1 | Mar 13, 2025 | |
RNA Avidity Biosciences | Initiates: Buy | $70 | $32.05 | +118.41% | 4 | Mar 13, 2025 | |
APGE Apogee Therapeutics | Initiates: Buy | $95 | $40.14 | +136.67% | 2 | Mar 13, 2025 | |
ETNB 89bio | Initiates: Buy | $25 | $8.02 | +211.72% | 1 | Mar 13, 2025 | |
BMRN BioMarin Pharmaceutical | Maintains: Buy | $99 → $103 | $71.48 | +44.10% | 3 | Feb 20, 2025 | |
BIIB Biogen | Maintains: Neutral | $160 → $145 | $142.43 | +1.80% | 14 | Feb 13, 2025 | |
ABBV AbbVie | Maintains: Buy | $205 → $215 | $201.30 | +6.81% | 16 | Feb 3, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $795 → $750 | $640.14 | +17.16% | 20 | Jan 28, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $295 | $305.71 | -3.50% | 11 | Jan 28, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $85 | $39.18 | +116.95% | 2 | Jan 7, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $112 → $4 | $2.18 | +83.49% | 5 | Jan 7, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $7 | $1.09 | +542.20% | 2 | Jan 6, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $45 | $36.10 | +24.65% | 5 | Nov 25, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $109.27 | +14.40% | 6 | Nov 14, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $575 | $500.28 | +14.94% | 4 | Nov 14, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,150 → $1,100 | $826.76 | +33.05% | 9 | Oct 31, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $1 | $0.56 | +79.28% | 3 | Oct 30, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $22 → $31 | $10.24 | +202.73% | 2 | Oct 18, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $10 | $0.40 | +2,400.00% | 2 | Aug 19, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $145 | $88.15 | +64.50% | 6 | Jul 31, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $170 | $161.72 | +5.12% | 3 | Apr 17, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $38 | $31.56 | +20.41% | 2 | Apr 12, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $48 | $30.12 | +59.36% | 2 | Mar 13, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $68 → $60 | $59.21 | +1.33% | 8 | Jan 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 | $1.23 | +550.41% | 2 | Dec 15, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $6.59 | +112.44% | 2 | Sep 8, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $10 → $8 | $2.85 | +180.70% | 4 | Aug 21, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $1.43 | +1,088.81% | 1 | Aug 21, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $14 | $1.16 | +1,106.90% | 3 | Jul 20, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $45 | $25.21 | +78.50% | 6 | Apr 21, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $3.81 | +1,212.34% | 1 | Jan 5, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $1.75 | +1,271.43% | 4 | Nov 1, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $4 | $8.52 | -53.05% | 2 | Jun 8, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $1.48 | +1,791.89% | 1 | Aug 10, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $0.56 | +6,015.11% | 1 | Jul 13, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $56 | $4.84 | +1,057.02% | 3 | May 7, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $35 | $1.63 | +2,047.24% | 4 | Jan 15, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $525 | $3.94 | +13,224.87% | 1 | Nov 23, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $1.16 | +3,520.69% | 1 | Oct 20, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $7.23 | +176.63% | 1 | Sep 15, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $0.85 | +2,266.86% | 2 | Sep 8, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underperform | $9 | $3.13 | +187.54% | 1 | Jun 25, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $8.20 | +631.71% | 1 | Jun 25, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $7 | $3.48 | +101.15% | 1 | Jun 25, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $23 | $12.35 | +86.23% | 3 | Aug 5, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $90 → $82 | $61.26 | +33.86% | 9 | May 3, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $95 | $310.82 | -69.44% | 6 | Mar 1, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $300 → $80 | $4.05 | +1,875.31% | 3 | Dec 20, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $43 → $40 | $55.31 | -27.68% | 7 | Nov 6, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $135 | $114.45 | +17.96% | 2 | Aug 1, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $13.37 | - | 4 | May 21, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $1.46 | +1,269.86% | 4 | May 3, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $28.86 | - | 2 | Apr 5, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $158 | $269.21 | -41.31% | 5 | Nov 8, 2017 |
Moderna
Mar 13, 2025
Initiates: Neutral
Price Target: $40
Current: $31.48
Upside: +27.06%
Kymera Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $52
Current: $30.39
Upside: +71.11%
Kiniksa Pharmaceuticals International,
Mar 13, 2025
Initiates: Buy
Price Target: $40
Current: $22.76
Upside: +75.75%
BioNTech SE
Mar 13, 2025
Initiates: Buy
Price Target: $145
Current: $95.90
Upside: +51.20%
Avidity Biosciences
Mar 13, 2025
Initiates: Buy
Price Target: $70
Current: $32.05
Upside: +118.41%
Apogee Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $95
Current: $40.14
Upside: +136.67%
89bio
Mar 13, 2025
Initiates: Buy
Price Target: $25
Current: $8.02
Upside: +211.72%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Buy
Price Target: $99 → $103
Current: $71.48
Upside: +44.10%
Biogen
Feb 13, 2025
Maintains: Neutral
Price Target: $160 → $145
Current: $142.43
Upside: +1.80%
AbbVie
Feb 3, 2025
Maintains: Buy
Price Target: $205 → $215
Current: $201.30
Upside: +6.81%
Jan 28, 2025
Maintains: Neutral
Price Target: $795 → $750
Current: $640.14
Upside: +17.16%
Jan 28, 2025
Maintains: Neutral
Price Target: $310 → $295
Current: $305.71
Upside: -3.50%
Jan 7, 2025
Maintains: Buy
Price Target: $98 → $85
Current: $39.18
Upside: +116.95%
Jan 7, 2025
Downgrades: Underperform
Price Target: $112 → $4
Current: $2.18
Upside: +83.49%
Jan 6, 2025
Maintains: Buy
Price Target: $22 → $7
Current: $1.09
Upside: +542.20%
Nov 25, 2024
Maintains: Buy
Price Target: $42 → $45
Current: $36.10
Upside: +24.65%
Nov 14, 2024
Initiates: Buy
Price Target: $125
Current: $109.27
Upside: +14.40%
Nov 14, 2024
Initiates: Buy
Price Target: $575
Current: $500.28
Upside: +14.94%
Oct 31, 2024
Maintains: Buy
Price Target: $1,150 → $1,100
Current: $826.76
Upside: +33.05%
Oct 30, 2024
Downgrades: Underperform
Price Target: $6 → $1
Current: $0.56
Upside: +79.28%
Oct 18, 2024
Upgrades: Buy
Price Target: $22 → $31
Current: $10.24
Upside: +202.73%
Aug 19, 2024
Maintains: Buy
Price Target: $12 → $10
Current: $0.40
Upside: +2,400.00%
Jul 31, 2024
Maintains: Buy
Price Target: $150 → $145
Current: $88.15
Upside: +64.50%
Apr 17, 2024
Maintains: Neutral
Price Target: $180 → $170
Current: $161.72
Upside: +5.12%
Apr 12, 2024
Maintains: Buy
Price Target: $40 → $38
Current: $31.56
Upside: +20.41%
Mar 13, 2024
Maintains: Buy
Price Target: $24 → $48
Current: $30.12
Upside: +59.36%
Jan 3, 2024
Downgrades: Neutral
Price Target: $68 → $60
Current: $59.21
Upside: +1.33%
Dec 15, 2023
Downgrades: Neutral
Price Target: $8
Current: $1.23
Upside: +550.41%
Sep 8, 2023
Downgrades: Neutral
Price Target: $23 → $14
Current: $6.59
Upside: +112.44%
Aug 21, 2023
Maintains: Underperform
Price Target: $10 → $8
Current: $2.85
Upside: +180.70%
Aug 21, 2023
Maintains: Buy
Price Target: $19 → $17
Current: $1.43
Upside: +1,088.81%
Jul 20, 2023
Reinstates: Buy
Price Target: $14
Current: $1.16
Upside: +1,106.90%
Apr 21, 2023
Maintains: Neutral
Price Target: $50 → $45
Current: $25.21
Upside: +78.50%
Jan 5, 2023
Initiates: Buy
Price Target: $50
Current: $3.81
Upside: +1,212.34%
Nov 1, 2022
Downgrades: Underperform
Price Target: $24
Current: $1.75
Upside: +1,271.43%
Jun 8, 2022
Downgrades: Neutral
Price Target: $12 → $4
Current: $8.52
Upside: -53.05%
Aug 10, 2021
Initiates: Buy
Price Target: $28
Current: $1.48
Upside: +1,791.89%
Jul 13, 2021
Initiates: Buy
Price Target: $34
Current: $0.56
Upside: +6,015.11%
May 7, 2021
Upgrades: Buy
Price Target: $56
Current: $4.84
Upside: +1,057.02%
Jan 15, 2021
Downgrades: Neutral
Price Target: $35
Current: $1.63
Upside: +2,047.24%
Nov 23, 2020
Initiates: Buy
Price Target: $525
Current: $3.94
Upside: +13,224.87%
Oct 20, 2020
Initiates: Buy
Price Target: $42
Current: $1.16
Upside: +3,520.69%
Sep 15, 2020
Reinstates: Buy
Price Target: $20
Current: $7.23
Upside: +176.63%
Sep 8, 2020
Reinstates: Buy
Price Target: $20
Current: $0.85
Upside: +2,266.86%
Jun 25, 2020
Reinstates: Underperform
Price Target: $9
Current: $3.13
Upside: +187.54%
Jun 25, 2020
Reinstates: Buy
Price Target: $60
Current: $8.20
Upside: +631.71%
Jun 25, 2020
Initiates: Underperform
Price Target: $7
Current: $3.48
Upside: +101.15%
Aug 5, 2019
Maintains: Equal-Weight
Price Target: $15 → $23
Current: $12.35
Upside: +86.23%
May 3, 2019
Downgrades: Equal-Weight
Price Target: $90 → $82
Current: $61.26
Upside: +33.86%
Mar 1, 2019
Maintains: Underweight
Price Target: $100 → $95
Current: $310.82
Upside: -69.44%
Dec 20, 2018
Downgrades: Equal-Weight
Price Target: $300 → $80
Current: $4.05
Upside: +1,875.31%
Nov 6, 2018
Maintains: Equal-Weight
Price Target: $43 → $40
Current: $55.31
Upside: -27.68%
Aug 1, 2018
Maintains: Overweight
Price Target: $100 → $135
Current: $114.45
Upside: +17.96%
May 21, 2018
Downgrades: Underweight
Price Target: n/a
Current: $13.37
Upside: -
May 3, 2018
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $1.46
Upside: +1,269.86%
Apr 5, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $28.86
Upside: -
Nov 8, 2017
Maintains: Overweight
Price Target: $127 → $158
Current: $269.21
Upside: -41.31%